Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer

被引:208
|
作者
Hoekstra, CJ
Stroobants, SG
Smit, EF
Vansteenkiste, J
van Tinteren, H
Postmus, PE
Golding, RP
Biesma, B
Schramel, FJHM
van Zandwijk, N
Lammertsma, AA
Hoekstra, OS
机构
[1] VU Univ, Med Ctr, Dept Nucl Med, NL-1007 MB Amsterdam, Netherlands
[2] VU Univ, Med Ctr, Positron Emiss Tomog Res, NL-1007 MB Amsterdam, Netherlands
[3] VU Univ, Med Ctr, Dept Pulm Med, NL-1007 MB Amsterdam, Netherlands
[4] VU Univ, Med Ctr, Dept Radiol, NL-1007 MB Amsterdam, Netherlands
[5] Jeroen Bosch Hosp, Dept Pulm Med, Shertogenbosch, Netherlands
[6] St Antonius Hosp, Dept Pulm Med, Nieuwegein, Netherlands
[7] Antoni Van Leeuwenhoek Hosp, Dept Thorac Oncol, Inst Canc, Amsterdam, Netherlands
[8] Ctr Comprehens Canc, Amsterdam, Netherlands
[9] Univ Hosp Gasthuisberg, Dept Nucl Med, B-3000 Louvain, Belgium
[10] Univ Hosp Gasthuisberg, Dept Pulm Med, B-3000 Louvain, Belgium
关键词
D O I
10.1200/JCO.2005.01.1189
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The objective of this study was to determine the accuracy of (early) response measurements using [F-18]-2-fluoro-2-deoxy-D-glucose positron emission tomography ((18)FDG PET) with respect to survival of patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC) undergoing induction chemotherapy (IQ, with a comparative analysis of PET methods. Patients and Methods In a prospective multicenter study, PET was performed in patients before IC and after one and three cycles. Computed tomography (CT) was performed before and after IC. Glucose consumption (metabolic rate of glucose [MRglu]) was measured using Patlak graphical analysis and correlated with simplified methods. Mediastinal lymph node (MLN) status was assessed visually. Cox proportional hazards analysis was used to determine the prognostic relevance of CT and PET measures of response with respect to survival. Results Complete PET data sets were available in 47 patients. Median survival was 21 months. MLN status after IC by PET predicted survival (hazard ratio [HR], 2.33; 95% Cl, 1.04 to 5.22; P = .04) in contrast with CT (HR, 1.87; 95% Cl, 0.81 to 4.30; P = .14). Residual MRglu after IC proved to be the best prognostic factor (HR, 1.95; 95% Cl, 1.28 to 2.97; P = .002). Multivariate stepwise analysis showed that PET identified prognostically different strata in patients considered responsive according to CT. Residual MRglu after one cycle selected patients with different outcomes (HR, 2.04; 95% Cl, 1.18 to 3.52; P = .01). Simplified quantitative (18)FDG PET methods were correlated with Patlak graphical analysis during and after therapy (r >= 0.90). Conclusion (18)FDG PET has additional value over CT in monitoring response to IC in patients with stage IIIA-N2 NSCLC, and it seems feasible to predict survival early during IC. Simple semiquantitative and complex PET methods perform equally well.
引用
收藏
页码:8362 / 8370
页数:9
相关论文
共 50 条
  • [21] Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer
    Mochiki, E
    Kuwano, H
    Katoh, H
    Asao, T
    Oriuchi, N
    Endo, K
    WORLD JOURNAL OF SURGERY, 2004, 28 (03) : 247 - 253
  • [22] Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging
    Fu-Li Wang
    Ye-Ying Tan
    Xiang-Min Gu
    Tian-Ran Li
    Guang-Ming Lu
    Gang Liu
    Tian-Long Huo
    中华医学杂志英文版, 2016, 129 (24) : 2926 - 2935
  • [23] Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging
    Wang, Fu-Li
    Tan, Ye-Ying
    Gu, Xiang-Min
    Li, Tian-Ran
    Lu, Guang-Ming
    Liu, Gang
    Huo, Tian-Long
    CHINESE MEDICAL JOURNAL, 2016, 129 (24) : 2926 - 2935
  • [24] Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma
    Cerfolio, RJ
    Ojha, B
    Mukherjee, S
    Pask, AH
    Bass, CS
    Katholi, CR
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (04): : 938 - 944
  • [25] CANCER-TREATMENT MONITORING WITH F-18 2-FLUORO-2-DEOXY-D-GLUCOSE AND POSITRON EMISSION TOMOGRAPHY - FRUSTRATION OR FUTURE
    MINN, H
    PAUL, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1992, 19 (11): : 921 - 924
  • [26] Efficient microscale synthesis of [18F]-2-fluoro-2-deoxy-D-glucose
    Koag, Myong Chul
    Kim, Hee-Kwon
    Kim, Andrew Sungjoon
    CHEMICAL ENGINEERING JOURNAL, 2014, 258 : 62 - 68
  • [27] Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer:: An analysis of 125 cases
    Vansteenkiste, JF
    Stroobants, SG
    Dupont, PJ
    De Leyn, PR
    Verbeken, EK
    Deneffe, GJ
    Mortelmans, LA
    Demedts, MG
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3201 - 3206
  • [28] Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma
    Ellebaek, Eva
    Schina, Aimilia
    Andersen, Rikke
    Hendel, Helle Westergren
    Svane, Inge Marie
    Donia, Marco
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (11) : 1870 - 1878
  • [29] Assessment of Interobserver Reproducibility in Quantitative [18F]-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography Measurements in Non-Small Cell Lung Cancer
    Han, Eun Ji
    Na, Sae Jung
    O, Joo Hyun
    Choi, Woo Hee
    JOURNAL OF MEDICAL IMAGING AND HEALTH INFORMATICS, 2016, 6 (05) : 1266 - 1270
  • [30] Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy
    Pöttgen, C
    Levegrün, S
    Theegarten, D
    Marnitz, S
    Grehl, S
    Pink, R
    Eberhardt, W
    Stamatis, G
    Gauler, T
    Antoch, G
    Bockisch, A
    Stuschke, M
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 97 - 106